UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR (I.R.S. Employer Identification No.) 11711 N. Meridian Street, Suite 300 Carmel, Indiana 46032 (Address of principal executive offices) (Zip Code) (317) 659-0200 Registrant's telephone number, including area code ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Exhibit 99.1 MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Post-bariatric Hypoglycemia (PBH): MBX 1416 • Phase 2 trial expected to be initiated in 2H 2025: In January, MBX reported Phase 1 top line results for its MBX 1416 long-acting GLP-1 receptor antagonist developed for the treatment of PBH. A Phase 2 trial is expected to be initiated in t ...

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision p ...

Results Release and Webinar Discussion on Morning of May 15, 2025MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025. At 11:00 AM ET on that day, Microbix ...

MBX Biosciences (MBX) 2025 Conference May 07, 2025 03:00 PM ET Speaker0 Thanks for sticking with us for the last, you know, couple sessions at the Citizens Life Sciences Conference. My name is John Walden, senior analyst here. We're pleased to have MBX Biosciences and CEO Kent Harlock joining us. This is actually a company we recently initiated coverage on, one of the more recent IPOs in the biotech space. So doing something that's very difficult to do, but we think a really interesting story with a competi ...

Sequel Pharma Executes Agreement with CDMO for Drug Product ManufacturingMISSISSAUGA, Ontario, May 05, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Dru ...

MISSISSAUGA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on Monday and Tuesday, May 5 & 6, 2025. The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and internati ...

MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter, announces that it will be attending and exhibiting at ESCMID Global 2025 and that a customer and collaborator will be presenting results of a pilot External Quality Assessment (EQA) program enabled by Microbix Quality Assessment Products (QAPs™). ESCMID Global is the Congress of the European Society of Clinical Microbiology and Infectiou ...

U.S. & Reciprocal Tariff Outcomes, Second-Half 2025 OutlookMISSISSAUGA, Ontario, April 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter, provides an update on U.S. and reciprocal tariff outcomes as well as business conditions and its outlook for the balance of its fiscal 2025. As has been widely reported, on April 2 the United States government imposed tariffs on certain goods (i.e., steel, alu ...

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company's Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical commercialization and executive leadership experience as well as a proven track r ...